ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1356

DAS28-CRP Cut-offs for High Disease Activity Assessment Is Lower Than DAS28-ESR in Rheumatoid Arthritis

Jacob Greenmyer1, John Stacy 1, James Beal 2 and Erdal Diri 1, 1University of North Dakota, School of Medicine Health Sciences, Minot, ND, 2University of North Dakota, School of Medicine Health Sciences, Grandforks, ND

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: DAS28-CRP and Disease Activity, DAS28-ESR, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rheumatoid arthritis (RA) disease activity and treatment response are usually assessed by using Disease Activity Score 28-joint count (DAS28), which can be calculated using erythrocyte sedimentation rate (ESR) or C reactive protein (CRP). It has been shown that DAS28-CRP values are lower than corresponding DAS28-ESR values, especially when assessing high disease activity. However, existing guidelines do not specify how cut-offs for high disease activity differ between these two calculations. Most existing studies that compare DAS28-CRP and DAS28-ESR are drawn largely on data from clinical trials or registries. Due to potential variation between laboratories and clinical assessment at separate institutions, existing data must be validated by and compared to data from single institutions. The relationship between high disease activity cut-offs for DAS28-ESR and DAS28-CRP must be carefully characterized in order to adequately assess clinical trial data. The purpose of our study was to compare the DAS28-ESR and DAS28-CRP values from a single institution.  

Methods: We conducted a chart review for new diagnoses of RA (ICD-9 714) from January 1, 2005 to September 1, 2018 at Trinity Health in Minot, ND. Patients were excluded if they (i) had received previous treatment with a DMARD, (ii) were currently receiving treatment with steroids upon referral, or (iii) did not contain the data necessary to calculate both ESR and CRP disease activity scores. Disease severity was calculated using the Disease Activity Scores DAS28-ESR and DAS28-CRP; these values were compared with t-test. P-values were two-sided, and p-value < 0.05 was considered significant. The number of patients with high disease activity ( > 5.1) was compared using ESR and CRP data to calculate the proportion of discordance. A receiver Operator Curve and Youden’s Index was used to calculate the DAS28-CRP high disease activity cut off estimation that corresponds to DAS28-ESR of > 5.1.

Results: A total of 171 newly diagnosed RA patients met inclusion criteria.  The mean DAS28-ESR of patients on presentation was 5.061 (SD = 1.15). The mean DAS-28 CRP was 4.134 (SD = .99). The difference between mean DAS28-ESR and DAS28-CRP was statistically significant (p < .001). The prevalence of patients who met high disease activity criteria ( > 5.1) for DAS28-ESR was 48.5% and for DAS28-CRP was 14.6%. Discordance between these two parameters was 33.9%. Kappa coefficient was .307, which corresponds to a minimal level of agreement. Receiver Operator Curve and Youden’s index analysis suggested that the cut off point for high disease activity of DAS28-CRP > 4.06, which corresponds to DAS28-ESR > 5.1.

Conclusion: There is a significant difference between DAS28-ESR and DAS28-CRP, especially when assessing high disease activity of RA, even if they are performed and calculated at a single institution.


Disclosure: J. Greenmyer, None; J. Stacy, None; J. Beal, None; E. Diri, None.

To cite this abstract in AMA style:

Greenmyer J, Stacy J, Beal J, Diri E. DAS28-CRP Cut-offs for High Disease Activity Assessment Is Lower Than DAS28-ESR in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/das28-crp-cut-offs-for-high-disease-activity-assessment-is-lower-than-das28-esr-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/das28-crp-cut-offs-for-high-disease-activity-assessment-is-lower-than-das28-esr-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology